PET/MRI advances efforts for virtual biopsy in breast cancer
FDG-PET/MRI combined with ultrasound could reduce the need for invasive biops...Read more on AuntMinnie.comRelated Reading: PET imaging shows how COVID vaccines confound cancer detection PET tracers reveal long-term consequences of brain injuries PET/MRI study looks at head injuries and Alzheimer's disease When will PET/MRI live up to its promise? FDG-PET/MRI offers option for pediatric Hodgkin lymphoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 27, 2021 Category: Radiology Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Investor Update - May 11, 2021 Category: Pharmaceuticals Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Media News - May 11, 2021 Category: Pharmaceuticals Source Type: news

Combo Provides'Broad Benefit' Across NHL Subtypes Combo Provides'Broad Benefit' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Combination-copanlisib-rituximab-significantly-increases-progression-free-survival-patients-relapsed
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with pre...
Source: Bayer Company News - April 10, 2021 Category: Pharmaceuticals Source Type: news

Cancer symptoms: Painless swellings may be a sign of non-Hodgkin lymphoma
CANCER will affect one in two of us, meaning 50 percent of the British population will get the deadly disease in their lifetime. What are the early warning signs of non-Hodgkin lymphoma? (Source: Daily Express - Health)
Source: Daily Express - Health - March 24, 2021 Category: Consumer Health News Source Type: news

PET/MRI study looks at head injuries and Alzheimer's disease
PET/MRI shows that a loss of cognitive function in older people due to hea...Read more on AuntMinnie.comRelated Reading: Siemens gets FDA clearance for new PET/CT scanner FDG-PET/MRI offers option for pediatric Hodgkin lymphoma PET identifies tau's origin in Alzheimer's disease PET shows aerobic exercise has little effect on amyloid ACR launches new PET/Alzheimer's study (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 18, 2021 Category: Radiology Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

Hodgkin's vs. Non-Hodgkin's Lymphoma
Title: Hodgkin's vs. Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 1/31/2007 12:00:00 AMLast Editorial Review: 11/10/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 10, 2020 Category: Cancer & Oncology Source Type: news

Non-Hodgkin's Lymphoma
Title: Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/31/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 31, 2020 Category: Cancer & Oncology Source Type: news

Experiences With Cancer, Captured in Works of Art
The program Brushes With Cancer pairs patients with artists whose works make visible a disease that can be invisible and isolating. (Source: NYT Health)
Source: NYT Health - August 26, 2020 Category: Consumer Health News Authors: Susan Gubar Tags: Art Breast Cancer Hodgkin ' s Lymphoma Ovarian Cancer Coronavirus (2019-nCoV) Source Type: news

WNBA ’s Elena Delle Donne Is ‘Hurt’ League Denied Her a Medical Waiver Despite Taking 64 Pills a Day
(NEW YORK) — WNBA MVP Elena Delle Donne was shocked and hurt when her request to be medically excused for the season was denied by an independent medical panel. Having battled Lyme disease for more than a decade and now taking 64 pills a day, she thought she was definitely going to be considered high-risk to get severe illness if she contracted the coronavirus. The panel of independent doctors the league and union agreed upon to make that decision thought otherwise, ruling Monday that she was not “high risk, and should be permitted to play in the bubble.” The disease is not included on the Centers for Di...
Source: TIME: Health - July 15, 2020 Category: Consumer Health News Authors: Doug Feinberg / AP Tags: Uncategorized Basketball COVID-19 News Desk wire Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

How Do You Get Non-Hodgkin ’s Lymphoma?
Title: How Do You Get Non-Hodgkin ’s Lymphoma?Category: Diseases and ConditionsCreated: 6/18/2020 12:00:00 AMLast Editorial Review: 6/18/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 18, 2020 Category: Cancer & Oncology Source Type: news

I'm 21 and have had chemotherapy during lockdown. I was one of the lucky ones
Since the start of the Covid-19 crisis, many hospitals have suspended routine cancer surgeries and chemotherapiesCoronavirus – latest updatesSee all our coronavirus coverageWhen I was diagnosed with stage four Hodgkin ’s lymphoma at the beginning of February, my mind immediately turned not to the illness and pain I knew would have to endure, but to the sadness of putting my life on pause. I could never have predicted that the world would end up putting its life on pause with me.My treatment – an intensive chemotherapy regimen – began on 4 March and finished on 12 May, coinciding closely with the UK ...
Source: Guardian Unlimited Science - May 26, 2020 Category: Science Authors: Madeleine Pulman-Jones Tags: Cancer Coronavirus outbreak Society Infectious diseases Medical research Microbiology Science World news Health NHS Hospitals & wellbeing Life and style Students Universities Education Higher education Society Professio Source Type: news

Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Risk for Hodgkin Lymphoma Increased With Allergic Disease, Eczema
Associations attenuated but remained significant after adjustment for steroid use (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 3, 2019 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Allergy, Oncology, Pathology, Journal, Source Type: news

Risk for Hodgkin Lymphoma Increased With Allergic Disease, Eczema
TUESDAY, Dec. 3, 2019 -- The risk for Hodgkin lymphoma (HL) is increased in association with immunosuppression, allergic disease, and eczema, according to a study published online Nov. 12 in the Journal of Allergy and Clinical Immunology. Meena... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2019 Category: Pharmaceuticals Source Type: news

FDA Takes Action to Reduce EtO Use
Shutdowns earlier this year of two facilities that use ethylene oxide (EtO) to sterilize medical devices prompted FDA to monitor for supply shortages in the industry because EtO is such a popular sterilization method for medical devices. This week the agency revealed steps it will take to reduce medtech's reliance on EtO sterilization. EtO is a flammable, colorless gas used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. Breathi...
Source: MDDI - November 25, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

Hodgkin Lymphoma | Medscape Hodgkin Lymphoma | Medscape
Review in-depth clinical information, latest medical news, and guidelines on Hodgkin lymphoma symptoms and Hodgkin's disease. Learn about Hodgkin's cancer and Hodgkin's lymphoma prognosis. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 4, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

Invasive fungal diseases before and after allogeneic hematopoietic stem cell transplantation in patients with hodgkin's lymphoma
Invasive fungal diseases before and after allogeneic hematopoietic stem cell transplantation in patients with hodgkin's lymphomaConference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 25, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

We Will Find a Breakthrough for Alzheimer ’s Disease
I have spent my entire career interested in the mysteries of the brain: what it looks like, how it works and what happens when it doesn’t. Alzheimer’s disease has been the primary focus of my professional life, starting as a young researcher looking at brain scans, and leading up to now, as the head of the research program at the Alzheimer’s Association. It’s also affected me personally. My family gradually noticed my mother-in-law’s declining memory, wandering and confusion in the late 2000s, and, in 2009, she was diagnosed with Alzheimer’s. As an expert on the illness, I was able to an...
Source: TIME: Health - October 24, 2019 Category: Consumer Health News Authors: Maria C. Carrillo Tags: Uncategorized Alzheimer's health HealthSummit19 Source Type: news

Medicare Now Covers CAR T-Cell Therapy for Approved Cancers
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Source: Asbestos and Mesothelioma News - September 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Featured Review: Imaging with PET during chemotherapy to predict outcome in adults with Hodgkin lymphoma
The objective of this review was to determine whether in previously untreated adults with HL (all stages) receiving first-line therapy, interim PET scan results (i.e. a positive or a negative result) can distinguish between those with a poor prognosis and those with a better prognosis, and thereby predict survival in each group.How many studies were included? What was included and what was excluded?We included twenty-three studies in total, in this review. In all studies, interim PET was conducted during first-line therapy and after two, three, and/or four cycles of chemotherapy in adults with HL (all stages). We included ...
Source: Cochrane News and Events - September 17, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news

Clinical Trial Offering Personalized Immunotherapy for Mesothelioma
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The phase I clinical trial involves a combination of Keytruda (pembrolizumab), a proven immunotherapy drug, and an individualized vaccine based upon the genetic mutations found in each patient’s cancer. “This is the future of cancer treatment,” Dr. Ezra Cohen, principal investigator and director of the San Diego Center for Precision Immunotherapy, told The Mesothelioma Center at Asbestos.com. “Now, we still ha...
Source: Asbestos and Mesothelioma News - August 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pediatric Lymphoma Joins Family of BRCA2 Cancers Pediatric Lymphoma Joins Family of BRCA2 Cancers
Researchers call for genetic testing of all survivors of pediatric non-Hodgkin lymphoma after data revealed BRCA2 is implicated in the childhood disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 26, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A bone marrow transplant saved boy, 10, from cancer - then nearly killed him
Danny Feltwell Jr, 10, suffered from non-Hodgkin lymphoma. A bone marrow transplant treated his relapse, but then he got graft-versus-host disease. An experimental treatment has him back to pitching. (Source: the Mail online | Health)
Source: the Mail online | Health - June 12, 2019 Category: Consumer Health News Source Type: news

Why Hodgkin's lymphoma cells grow uncontrollably
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) Although classical Hodgkin's lymphoma is generally easily treatable today, many aspects of the disease still remain a mystery. A team at the Max Delbr ü ck Center led by Professor Claus Scheidereit has now identified an important signaling molecule in the biology of this lymphoma: LTA. It helps the cancer to grow unimpeded - for example, by activating genes for immune checkpoint ligands that protect tumor cells from the body's built-in defense system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2019 Category: International Medicine & Public Health Source Type: news

CD30: From witness to culprit
(Helmholtz Zentrum M ü nchen - German Research Center for Environmental Health) Cells of certain blood cancers such as Hodgkin's lymphoma carry the protein CD30 on their surface. The molecule is not only an indicator of a few cancers of the immune system but also increases the risk of their occurrence, according to a report in the journal Blood by researchers of the Helmholtz Zentrum M ü nchen. A greatly increased number of CD30-bearing cells are produced after certain viral infections, e.g. Epstein-Barr virus (EBV) infection, and in autoimmune diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2019 Category: Cancer & Oncology Source Type: news

A Man May Be Cleared of HIV for the Second Time in History. Here ’s What That Means
A man in London has become only the second person to achieve remission from HIV infection, researchers from the UK reported Tuesday. The therapy responsible has worked on only one other person who is considered to be “cured” of HIV: Timothy Ray Brown, who still does not show signs of the virus in his body after more than 10 years. Here’s what to know about the landmark case. How did it happen? In a letter published in the journal Nature, researchers led by Ravindra Gupta from the University of Cambridge London and Imperial College London and his colleagues say that they used a treatment similar to the one...
Source: TIME: Health - March 5, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV/AIDS Source Type: news

‘London Patient’ Appears to Become the Second Person Ever Cured of HIV
Doctors say a British man who previously tested positive for HIV might be the second person ever to be cured of the virus that causes AIDS. Reuters reports that the man, whose identity has not been revealed, has tested negative for the virus almost three years after he received a bone marrow transplant from a donor with an HIV-resistant genetic mutation. The man stopped taking antiretroviral drugs 18 months ago. “There is no virus there that we can measure. We can’t detect anything,” Ravindra Gupta, the doctor who co-lead the man’s treatment team, told Reuters. The man, who has been dubbed the &ldqu...
Source: TIME: Health - March 5, 2019 Category: Consumer Health News Authors: Amy Gunia Tags: Uncategorized health HIV/AIDS onetime overnight Source Type: news

‘London Patient’ Appears to Become the Second Person Ever Cured of AIDS
Doctors say a British man who previously tested positive for HIV might be the second person ever to be cured of the AIDS virus. Reuters reports that the man, whose identity has not been revealed, has tested negative for the virus almost three years after he received a bone marrow transplant from a donor with an HIV-resistant genetic mutation. The man stopped taking antiretroviral drugs 18 months ago. “There is no virus there that we can measure. We can’t detect anything,” Ravindra Gupta, the doctor who co-lead the man’s treatment team, told Reuters. The man, who has been dubbed the “London pat...
Source: TIME: Health - March 5, 2019 Category: Consumer Health News Authors: Amy Gunia Tags: Uncategorized health HIV/AIDS onetime overnight Source Type: news

Studies suggest immunotherapy adds punch to earlier attempts
(NYU Langone Health / NYU School of Medicine) New drugs that harness the body's immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists say, even for repeat drug therapies whose initial attempts failed to stop or reverse the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2018 Category: Cancer & Oncology Source Type: news

Non-Hodgkin Lymphoma | Medscape Non-Hodgkin Lymphoma | Medscape
Non-Hodgkin lymphoma is the fifth most common cancer in the United States, accounting for about 4% of all malignancies in both men and women. The disease comprises a variety of cancers of the lymphatic system exclusive of Hodgkin lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news

I Won a Historic Lawsuit, But May Not Live to Get the Money
Dewayne Anthony Lee Johnson has always just gone by Lee. He lived a modest life for 42 years, and was devastated when he was diagnosed with terminal cancer in 2014. Now 46, as he struggles with his advancing illness, Johnson has found sudden celebrity with a historic victory over one of the world’s most powerful and controversial corporations – Monsanto Co. Johnson sued Monsanto alleging that he developed a deadly form of non-Hodgkin lymphoma after being drenched with the company’s herbicides, which he sprayed as part of his job as school groundskeeper. In Aug. 2018, a jury in San Francisco unanimously f...
Source: TIME: Health - November 21, 2018 Category: Consumer Health News Authors: Carey Gillam Tags: Uncategorized Cancer monsanto Source Type: news

Paul Allen ’s death shines light on non-Hodgkin lymphoma
The co-founder of Microsoft died Monday from complications with the disease, which is one of the most common cancers in the United States (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 16, 2018 Category: Consumer Health News Source Type: news

Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping po...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news

Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping po...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Cancer in Adolescence and Young Adulthood Linked to Endocrine Disease (CME/CE)
(MedPage Today) -- Association was strongest for leukemia, Hodgkin lymphoma, and brain cancer (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - June 29, 2018 Category: Endocrinology Source Type: news

VHIO is the first Spanish site to conduct CAR T cell trial against lymphoma in Europe
(Vall d'Hebron Institute of Oncology) Launched: First international clinical trial with CAR T cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma (B-Cell NHL) in Europe.The trial has been designed to determine the efficacy and safety of JCAR017, a chimeric antigen receptor (CAR) T cell therapy, in the treatment of clinically selected adult patients with relapsed or refractory disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2018 Category: International Medicine & Public Health Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Approval of Brentuximab Vedotin With Chemo Offers New Hope for Stage III/IV Hodgkin Lymphoma
Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years. (Source: CancerNetwork)
Source: CancerNetwork - March 22, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news

For one early adopter, CAR T therapy means 18 months cancer-free and counting
For as long as he can remember, Josh Feldman has eagerly embraced the latest technology.Decades ago, his family was the first one on the block with a VCR. Years later, when television went hi-def, he acquired a big-screen TV and signed up for HD service.So after he was diagnosed with lymphoma, it was only natural that Feldman was driven to join clinical trials for a promising new treatment. He would become one of the first UCLA Health patients to receive CAR T therapy. When nothing else worked, the treatment beat back cancer and filled his life with new hope.“Years ago, while doing my own reading after my diagnosis, ...
Source: UCLA Newsroom: Health Sciences - February 14, 2018 Category: Universities & Medical Training Source Type: news

Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news

Engineered Tumor-Specific T-Cells May Help Relapsed Hodgkin Lymphoma Patients
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T-cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma
(Children's National Health System) A research team that includes Children's National Health System clinician-researchers has validated a way to outfox tumors. They engineered T-cells, essential players in the body's own immune system, to strip tumors of their self-preservation skill and were able to hold Hodgkin lymphoma at bay in patients with relapsed disease for more than four years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2018 Category: International Medicine & Public Health Source Type: news